PUMA BIOTECHNOLOGY, INC. Finite-Lived Intangible Asset, Expected Amortization, after Year Five
PUMA BIOTECHNOLOGY, INC. (PBYI) had Finite-Lived Intangible Asset, Expected Amortization, after Year Five of $2.44 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive · last filed 2025-02-27
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $2.44M.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $12.18M.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $21.91M.
- 2021-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $26.05M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, after Year Five |
|---|---|
| 2024-12-31 | $2.44M 10-K · filed 2025-02-27 |
| 2023-12-31 | $12.18M 10-K · filed 2024-02-29 |
| 2022-12-31 | $21.91M 10-K · filed 2023-03-02 |
| 2021-12-31 | $26.05M 10-K · filed 2022-03-03 |
| 2020-12-31 | $34.06M 10-K · filed 2021-03-01 |
| 2019-12-31 | $20.73M 10-K · filed 2020-02-28 |
| 2017-12-31 | $28.62M 10-K · filed 2018-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |